These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15367403)

  • 41. Doublet chemotherapy vs. single-agent therapy with 5FU in elderly patients with metastatic colorectal cancer. a meta-analysis.
    Landre T; Uzzan B; Nicolas P; Aparicio T; Zelek L; Mary F; Taleb C; Des Guetz G
    Int J Colorectal Dis; 2015 Oct; 30(10):1305-10. PubMed ID: 26099322
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Rubbia-Brandt L; Giostra E; Brezault C; Roth AD; Andres A; Audard V; Sartoretti P; Dousset B; Majno PE; Soubrane O; Chaussade S; Mentha G; Terris B
    Ann Oncol; 2007 Feb; 18(2):299-304. PubMed ID: 17060484
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy of postoperative oxaliplatin- or irinotecan-based chemotherapy after curative resection of synchronous liver metastases from colorectal cancer.
    Hsu HC; Chou WC; Shen WC; Wu CE; Chen JS; Liau CT; Lin YC; Yang TS
    Anticancer Res; 2013 Aug; 33(8):3317-25. PubMed ID: 23898098
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Capecitabine in combination with irinotecan or oxaliplatin in advanced colorectal cancer.
    Clin Colorectal Cancer; 2003 Aug; 3(2):89-91. PubMed ID: 12952563
    [No Abstract]   [Full Text] [Related]  

  • 45. [New therapeutic options in chemotherapy of advanced colorectal cancer].
    Reimer P; Rückle-Lanz H
    Med Klin (Munich); 2001 Oct; 96(10):593-8. PubMed ID: 11715331
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Economic impact of simplified de Gramont regimen in first-line therapy in metastatic colorectal cancer.
    Limat S; Bracco-Nolin CH; Legat-Fagnoni C; Chaigneau L; Stein U; Huchet B; Pivot X; Woronoff-Lemsi MC
    Eur J Health Econ; 2006 Jun; 7(2):107-13. PubMed ID: 16474968
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of oxaliplatin in the treatment of advanced metastatic colorectal cancer: prospects and future directions.
    Schmoll HJ
    Semin Oncol; 2002 Oct; 29(5 Suppl 15):34-9. PubMed ID: 12422306
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Evidence-based update of chemotherapy options for metastatic colorectal cancer.
    Damjanovic D; Thompson P; Findlay MP
    ANZ J Surg; 2004 Sep; 74(9):781-7. PubMed ID: 15379811
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
    Bartlett DL; Berlin J; Lauwers GY; Messersmith WA; Petrelli NJ; Venook AP
    Ann Surg Oncol; 2006 Oct; 13(10):1284-92. PubMed ID: 16955384
    [No Abstract]   [Full Text] [Related]  

  • 50. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients.
    Gil-Delgado MA; Bastian G; Guinet F; Spano JP; Taillibert S; Rocher MA; Castaing D; Adam R; Urien S; Bismuth H; Khayat D
    Am J Clin Oncol; 2004 Jun; 27(3):294-8. PubMed ID: 15170151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Irinotecan or oxaliplatin for first-line treatment of advanced colorectal cancer?
    Punt CJ
    Ann Oncol; 2005 Jun; 16(6):845-6. PubMed ID: 15890668
    [No Abstract]   [Full Text] [Related]  

  • 52. First-line treatment strategies to improve survival in patients with advanced colorectal cancer.
    Gill S; Goldberg RM
    Drugs; 2004; 64(1):27-44. PubMed ID: 14723557
    [TBL] [Abstract][Full Text] [Related]  

  • 53. New developments in systemic chemotherapy in advanced colorectal cancer.
    Cats A
    Scand J Gastroenterol Suppl; 2003; (239):78-86. PubMed ID: 14743888
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Single-agent irinotecan or FOLFIRI as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis [corrected].
    Clarke SJ; Yip S; Brown C; van Hazel GA; Ransom DT; Goldstein D; Jeffrey GM; Tebbutt NC; Buck M; Lowenthal RM; Boland A; Gebski V; Zalcberg J; Simes RJ;
    Eur J Cancer; 2011 Aug; 47(12):1826-36. PubMed ID: 21665462
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
    Reddy SK; Morse MA; Hurwitz HI; Bendell JC; Gan TJ; Hill SE; Clary BM
    J Am Coll Surg; 2008 Jan; 206(1):96-106. PubMed ID: 18155574
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New oxaliplatin-based combinations in the treatment of colorectal cancer.
    Cassidy J; Hochster H
    Colorectal Dis; 2003 Nov; 5 Suppl 3():1-9. PubMed ID: 23573555
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Randomized phase II study of irinotecan plus mitomycin C vs. oxaliplatin plus mitomycin C in patients with advanced fluoropyrimidine/leucovorin-pretreated colorectal cancer.
    Scheithauer W; Kornek GV; Brugger S; Ullrich-Pur H; Valencak J; Raderer M; Fiebiger W; Kovats E; Lang F; Depisch D
    Cancer Invest; 2002; 20(1):60-8. PubMed ID: 11853004
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Irinotecan in metastatic colorectal cancer: dose intensification and combination with new agents, including biological response modifiers.
    Ducreux M; Köhne CH; Schwartz GK; Vanhoefer U
    Ann Oncol; 2003; 14 Suppl 2():ii17-23. PubMed ID: 12810453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Enhancing oxaliplatin-based regimens in colorectal cancer by inhibiting the epidermal growth factor receptor pathway.
    Kim GP; Grothey A
    Clin Colorectal Cancer; 2005 Nov; 5 Suppl 2():S89-97. PubMed ID: 16336754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Pfeiffer P; Sørbye H; Ehrsson H; Fokstuen T; Mortensen JP; Baltesgard L; Tveit KM; Øgreid D; Starkhammar H; Wallin I; Qvortrup C; Glimelius B
    Ann Oncol; 2006 Feb; 17(2):252-8. PubMed ID: 16291583
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.